PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

The tool, called AIM-NASH (Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology) from Boston-based Path AI, supports pathologists in analyzing liver biopsy scans to ...

“A robust, automated and highly standardized method to assess liver histological ... of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

"A robust, automated and highly standardized method to assess liver histological lesions ... Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...

SINGAPORE, March 17, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology ... landscape of liver disease management. Metabolic dysfunction-associated steatohepatitis ...